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Abstract
Background: Chemotherapy for lymph nodes cancer is often composed of several drugs that are used in a treatment program. 
Objectives: The aim of this study was to perform a cost-utility analysis of IEV regimen (ifosfamide, epirubicin and etoposide) versus ESHAP 
regimen (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in patients with lymphoma in the south of Iran.
Patients and Methods: This was a cost-utility analysis done as a cross-sectional study in the south of Iran. Using decision tree, expected 
costs, quality -adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) were estimated. In addition, the robustness of 
results was examined by sensitivity analysis.
Results: The results of this study indicated that the total lymphoma patients were about 65 people that 27 patients received IEV regimen 
and 38 patients ESHAP (43 patients with Hodgkin’s and 22 with non-Hodgkin lymphoma). The results of decision tree showed that in the 
IEV arm, the expected cost was $20952.93 and the expected QALYs was 3.89 and in the ESHAP arm, the expected cost was $31691.74 and the 
expected QALYs was 3.86. Based on the results of the study, IEV regimen was cost-effective alternative to the ESHAP regimen.
Conclusions: According to the results of this study, it is recommended that oncologists use IEV instead of ESHAP in the treatment of 
patients with lymphoma and because of high costs of IEV drug costs, it is suggested that IEV drugs should be covered by insurance.
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1. Background
14 million cases of cancer are diagnosed annually and 
the number of cancer patients will reach 24 million peo-
ple in the world by the year 2035 (1). In 2012, in the Unit-
ed States, the death rate from lymphoma, both among 
women and men, included 3% of all cases of death (2). In 
2008, in Canada, 7,000 new cases were detected and 3,100 
deaths occurred approximately (3). The non-Hodgkin’s 
lymphomas are the second cancer rising, both in terms 
of incidence and mortality, and its incidence has doubled 
since 1970 (4). Non-Hodgkin’s lymphomas are the most 
common hematologic malignancy among adults in the 
world (5) and the sixth type of malignant neoplasm in 
the United States (6). The incidence of Hodgkin’s lym-
phomas in the United States and England is 2.7 to 2.8 per 
100,000, and 1,700 new cases are identified annually (7).
In Iran, cancer is the third leading cause of death after 
cardiovascular diseases and accidents. It is estimated 
that more than 70,000 new cases of cancer occur ev-
ery year in the country (8). In 2009, the total number 
of cancer cases reported were 74,067 people, 55.58% in 
males and 44.42% in females. In the meantime, the age-
standardized incidence rate of Lymphoma cancer is 4.57 
among men in Fars province (9).
Due to the increase in life expectancy and lifestyle choic-
es related to cancer, the burden of cancer is increasing in 
developing countries (10). The study of Khajedaluee et al. 
in Mashhad, Iranindicated that the most disability adjust-
ed life years (DALY) were attributed to gastric, leukemia 
and lung cancers and the maximum DALY was related to 
breast cancer in women aged 30 - 44 years old (11). Murray 
et al. in a study concluded that stomach cancer, other neo-
plasms, liver cancer, and trachea, bronchus, and lung can-
cers caused more than 15 million DALYs (12). In one study in 
Australia in 2001, years life lost (YLL) constituted 78% of the 
overall DALYs associated with cancer (13).
Because cancer is considered a chronic disease, it im-
pacts the lives of many people in all ages (14). National 
Institute for America’s Health, in 2010, estimated overall 
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costs of cancer to be about 263.8 billion that includes di-
rect costs ($102.2 billion), indirect costs due to illness, or 
loss of productivity due to illness ($20.9 billion) and in-
direct costs due to mortality or reduced productivity due 
to premature death ($140) (15). Therefore, one can say 
that after the damage, death and destruction of human, 
the most important aspect of cancer is the economic 
aspects and costs that are imposed on the lives of indi-
viduals and communities (16). Therefore, it is important 
to measure the quality of life and cost-effectiveness, and 
costs as well as quality should be measured in order to 
make decisions about utilization of resources (17).
Many patients with lymphatic cancer received chemo-
therapy as part of their treatment. Chemotherapy for 
cancer of the lymph nodes is often composed of several 
drugs that are used in a treatment program. Although 
lymphomas are potentially curable with standard che-
motherapy, many patients either relapse or never achieve 
remission unless they use high dose chemotherapy (18). 
One of these methods is ESHAP regimen, a combination 
of the chemotherapeutic drugs etoposide, methylpred-
nisolone, high-dose cytarabine, and cisplatin (19), and it 
has been shown to be active against refractory or relapsed 
lymphoma (20). Another method is IEV, a combination of 
three drugs Ifosfamide, epirubicin, and etoposide (21). 
2. Objectives
Due to the various medical expenses in the use of these 
two methods and, consequently, different financial and 
economic burden on the health system and also the lim-
ited knowledge about the costs and their effectiveness, 
the researcher aimed to do a study to determine the cost-
utility IEV versus ESHAP, which is used commonly in treat-
ment of lymphoma in Iran.
3. Patients and Methods
This study was a cost- utility analysis done as a cross-
sectional study in Amir Hospital in Shiraz, in the south 
of Iran. The study was conducted on patients who were 
admitted in Amir Hospital for chemotherapy in 2013. 
According to hospital statistics, in this period, approxi-
mately lymphoma patients were about 65 people, 27 of 
whom had received IEV and 38 patients ESHAP. Therefore, 
sampling was not done and all patients were included in 
the study. All of them underwent one of the two methods: 
IEV and ESHAP. When using these two methods, courses 
were repeated every 21 days about 3 - 4 times (21). To de-
termine the cost-utility of IEV versus ESHAP, the decision 
tree was used. These patients responded to chemothera-
py in three forms: complete response, partial response, 
non-response, complete response (CR) was defined as the 
complete disappearance of signs and symptoms due to 
lymphoma and maintained for at least 6 weeks; partial 
response (PR) was defined as a reduction of at least 50% 
in the product of the two largest perpendicular diam-
eters of all measurable lesions for a duration of at least 6 
weeks. Progression of disease (PD) or non- response was 
used where there was unequivocal evidence of advancing 
disease, despite continuation of the treatment (22).
First, using this model, the expected costs and QALY were 
calculated for both methods and the incremental cost-ef-
fectiveness ratio was measured; it was defined as the ratio 
of the difference between the expected cost and expected 
QALY. In this study, a decision tree model was used to ex-
amine the cost and effectiveness of IEV and ESHAP. The de-
cision tree model is a graphic representation of the path-
ways of diagnosis and treatment of different diseases in 
which the probabilities, costs and consequences of path-
ways are shown. The decision tree was shown in Figure 1.
Data for this study was divided into two parts: utility 
and costs. The costs were identified and measured from 
social perspective. These items include medical and non- 
medical direct costs and indirect costs. In this study, a 
data collection form was used to collect data. It consisted 
of two parts. The first part included demographic data of 
the patients and the second section contained informa-
tion about the therapy and pharmaceutical costs, diag-
nostic and laboratory (lab, radiology, MRI, etc.), the cost 
of accommodation and traveling and related expenses 
during chemotherapy. It should be noted that indirect 
costs are calculated using the human capital approach 
and because the study period was one year, we did not use 
the discount rate. To assess the utility of two regimens, 
the European organization for research and treatment of 
cancer quality of life questionnaire-core30 (EORTC QLQ-
C30) was used (23). This questionnaire consisted of per-
formance scale (physical, role, emotional, cognitive and 
social), symptom scale (dyspnea, insomnia, appetite loss, 
constipation, diarrhea and financial difficulties, fatigue, 
nausea and vomiting, pain), and an overall health-status 
scale. In the questionnaire, raw scores are considered 
from 0 to 100 and the highest score represents a high 
level of functioning, excluding symptom scales in which 
high scores represent a high level of symptoms. In gen-
eral, this questionnaire reports separate scores for each 
dimension. First, using the weighted scores of quality of 
life, we calculated the utility (between zero and one) final-
ly; the QALY was measured by multiplying the amount of 
utility in the treatment period (6 months or half a year).
The data was collected in this part of the study by inter-
viewing the patient one month after the last chemotherapy 
because according to oncology experts, drug effect emerg-
es one month after chemotherapy. We also used the con-
tact number of patients, available in patient records, des-
ignated time and place of the interview. At the beginning 
of each interview, the overall goal of the project and inter-
view was explained to each patient separately. The patients 
who were interested in participation answered questions 
fully informed and voluntarily. Next, the researcher col-
lected cost data through data collection forms and data on 
utilities by using a questionnaire (EORTC QLQ-C30). In this 
section, these data (cost and utility) were simultaneously 
obtained from the patient. However, during the interview, 
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the interviewer was unaware of the treatment protocol 
because the study was designed as a double blind study. 
This increases the accuracy of the interview. At this stage, 
only the patient record numbers were recorded on a de-
mographic questionnaire. Then, the researchers recorded 
treatment protocol by referring to the patient records. To 
perform this analysis, Treeage 2011 and SPSS 16.0 specific 
software were used as well as descriptive statistical analy-
sis. Also, the Mann-Whitney test was used to determine the 
significant differences in costs between the two groups. 
Also, 95% confidence intervals (CIs) were calculated using 
non-parametric bootstrapping approach for cost and QALY. 
By the decision tree, the expected costs and QALY were cal-
culated and to increase the accuracy of the study, one-way 
deterministic sensitivity analysis (Tornado Diagram) and 
probabilistic sensitivity analysis were performed.
4. Results
Based on the results of the present study, of the 65 pa-
tients studied, 66.1% were male, 67.7% were married, 60% 
were aged less than 40 years and all patients had insurance.
 Table 1 shows the mean QALY in patients, using two dif-
ferent regimens of IEV and ESHAP. According to the re-
sults, in the IEV, the QALY’s mean was 0.3676 (in Hodgkin 
lymphoma, 0.3712 and in non-Hodgkin lymphoma 0.362) 
and in the ESHAP; the QALY’s mean was 0.3029 (in Hodgkin 
lymphoma, 0.3065 and in non-Hodgkin lymphoma, 0.295).
According to Table 2, in both IEV and ESHAP, the mean 
of medical direct costs was the highest (1191.1 and 1819.57 
dollars, respectively) and that of non-medical direct costs 
was minimum (237.06 and 208.39 dollars, respectively). As 
seen in Table 2, the mean of medical direct costs was sig-
nificant in both IEV and ESHAP (P = 0.0001). But the means 
of non-medical direct costs, indirect costs and total cost dif-
ference were not significant statistically. As seen in Table 3, 
the mean cost of chemotherapy in the IEV was 488.94 dol-
lars that is the highest type of medical direct costs. Also, 
in the ESHAP, the cost of chemotherapy was 866.92 dollars 
and it was the highest medical direct costs. Travel costs and 
indirect costs of the patients were respectively the highest 
type of non-medical direct costs and indirect costs in both 
(in the IEV, 149.52 and 562.2 dollars and in the ESHAP 104.75 
and 351.65 dollars, respectively).
The results of decision tree in Figure 1 showed that in 
the IEV arm, the expected cost was 20952.93 dollars and 
the expected QALYs were 3.89 and in the ESHAP arm, the 
expected cost was 31691.74 dollars and the expected QALYs 
were 3.86. Therefore, IEV is dominant compared to ESHAP 
(less costly and more effective).
4.1. Sensitivity Analysis
Given that any economic evaluation study accompa-
nies uncertainty, in this study the effects of uncertainty 
were examined using one-way and probabilistic sensitiv-
ity analysis. In the one-way sensitivity analysis, the value 
of each variable increased by 20%; in order to create the 
tornado diagram (24). According to the tornado diagram 
in Figure 2, changes in most of the input parameters 
had a few effects on the outcome. The incremental cost-
effectiveness ratio (ICER) had high sensitivity to QALY of 
patients who did not respond to ESHAP and had low sen-
sitivity to the cost of patients who did not respond to IEV.
 Figure 3 indicated the results of probabilistic sensitiv-
ity analysis using Monte Carlo simulation of incremen-
tal costs and QALYs IEV versus ESHAP. For each one of the 
10,000 iterations, values for parameters were randomly 
selected from their probability distributions and results 
showed in 97% of the iterations, IEV was a dominant strat-
egy. In other words, IEV was estimated to have a lower 
cost and greater QALYs than ESHAP. In addition, maxi-
mum willingness to pay (threshold) was calculated based 
on WHO method (three times of Gross Domestic Product 
per capita, $9395.4) (25).
 
Lymphoma Patients
LEV Drug Regimen
Complete Response
Partial Response
No Response
No Response
Complete Response
Partial Response
ESHAP Drug
Regimen
Figure 1. Decision Tree of IEV Versus ESHAP
Table 1. QALY Value Based on the Type of Lymphoma
Type of 
Lymphoma
Type of Treatment 
Protocol
Number of 
Patients
QALY a
Hodgkin
IEV 17 0.3712 ± 0.0754
ESHAP 26 0.3065 ± 0.0651
Non-Hodgkin
IEV 10 0.362 ± 0.0885
ESHAP 12 0.295 ± 0.0602
Total
IEV 27 0.3676 ± 0.0789
ESHAP 38 0.3029 ± 0.063
aData are presented as mean ± SD.
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Table 2. The Cost of Cancer Patients With Lymph Node Based on the Type of Costs
Type of Treatment 
ProtocolCosts Mean
IEV ESHAP P-Value
Medical direct costs 1191.1 ± 610.74 1819.57 ± 789.73 0.0001
Non-medical direct costs 237.06 ± 207.42 208.39 ± 179.7 0.545
Indirect costs 598.24 ± 584.25 456.83 ± 666.09 0.249
Total 2026.42 ± 916.91 2484.79 ±1060.27 0.123
Table 3. The Cost Components of IEV and Eshap in Lymphatic Cancer as Included in the Analysisa
Strategy IEV ESHAP
Medical direct costs 1191.1 ± 610.74 1819.57 ± 789.73
Medication 488.94 ± 338.57 866.92 ± 354.91
Hospitalization 127.84 ± 30.25 261.35 ± 94.32
Sonography 20.63 ± 35.34 20.39 ± 34.09
Radiology 53.37 ± 42.38 72.4 ± 54.05
MRI 10.46 ± 25.12 16.36 ± 34.88
Surgical cost 160.73 ± 399.53 113.14 ± 164.96
Laboratory tests 143.09 ± 76.89 231.6 ± 210.90
CT-sCAN 71.47 ± 81.39 77.76 ± 80.56
Visits 22.57 ± 24.23 26.28 ± 21.61
Other 91.95 ± 389.42 133.33 ± 420.12
Non-medical direct costs 237.06 ± 207.42 208.39 ± 179.7
Traveling 149.52 ± 142.95 104.75 ± 98.56
Lodging 48.89 ± 77.24 55.56 ± 102.37
Phone 25.19 ± 23.78 23.42 ± 14.32
Auxiliary equipment 4.78 ± 23.30 1.8 ± 7.31
Special diet 8.67 ± 14.50 22.84 ± 34.52
Indirect costs 598.24 ± 584.25 456.83 ± 666.09
Time spent by the patient 562.2 ± 606.49 351.65 ± 655.41
Time spent by the patient’s accompany 36.03 ± 52.98 105.17 ± 280.48
Total 2026.42 ± 916.91 2484.79 ±1060.27
aData are presented as mean ± SD.
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Figure 2. Results of One-Way Sensitivity Analysis (Tornado Diagram)
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Figure 3. Results of Probabilistic Sensitivity Analysis (Each Point Indicates the Differences in Costs and QALYs for IEV vs. ESHAP)
5. Discussion
The costs and consequences of interventions and pro-
grams are compared in economic evaluation for the 
optimal use of scarce resources. Therefore, the aim of 
this study was to perform a cost-utility analysis of IEV 
versus ESHAP in patients with lymphoma. To our knowl-
edge, this is the first full economic evaluation study in 
patients with lymphoma in Iran. Because lymphoma is 
among the ten most common cancers and also cancer 
is the third leading cause of death in Iran; besides, IEV 
and ESHAP medication regimens are common drugs in 
the treatment of lymphoma, the discussion about the 
effectiveness and costs associated with them is of great 
importance. 
The findings of this study showed that the average di-
rect cost of treatment in IEV and ESHAP arms were 119,1.1 
and 181,9.57 dollars respectively and the difference was 
significant (P value = 0.0001). However, a significant 
difference was not observed between the mean of non-
medical direct costs and indirect costs in two arms. 
Also, the mean cost of chemotherapy was 866.92 dol-
lars in the ESHAP arm; it is 47.7% of medical direct costs. 
However, the mean cost of chemotherapy was 866.92 
dollars in the IEV arm, which is 41.04% of direct costs. 
In addition, the mean length of stay for each period of 
chemotherapy was 3 days in the IEV arm and 5 days in 
the ESHAP arm. These results could be due to the high-
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er cost of chemotherapy in the ESHAP and probably a 
lengthier stay would lead to more paraclinical costs. 
Hackshaw et al. (26), Woronoff-Lemsi et al. (27), Johnston 
et al. (28), Leese et al. (29), Ray et al. (30) and Kuderer et 
al. (31) in their study concluded that the main cost driv-
ers were medical direct costs especially chemotherapy 
drugs and medical direct costs were higher because of 
the higher cost of chemotherapy. Also, earlier discharge 
of patients with lymphoma would lead to reducing the 
length of stay and the medical direct costs.
Based on the results of this study, the means of QALY’s 
were 0.3676 and 0.3029 in the IEV and ESHAP arms, re-
spectively. In the meantime, the mean of QALY in pa-
tients with Hodgkin’s lymphoma was 0.3712 and 0.3065, 
and in patients with non-Hodgkin’s lymphoma it was 
0.362 and 0.295 for the IEV and ESHAP arms, respective-
ly. Based on the findings of this study, it can be stated 
that quality of life of patients who had received ESHAP 
is lower than those who had received IEV. This could be 
because of the lengthier stay for these patients, having 
a more negative impact on quality of life or may be due 
to the appropriate dose in the IEV than ESHAP. Hjerms-
tad et al. (32) in their study concluded that the length 
of stay has much impact on activities including work, 
family and social and daily activities, affecting their 
quality of life. So they will have a better quality in func-
tional and emotional dimensions if their length of stay 
is shorter. Also, Hasanpoor et al. indicated that there 
was a significant relationship between quality of life 
and type of cancer (33). Also, Mols et al. (34), Webster 
and Cella (35) and van Dis et al. (36) indicated that pa-
tients who received chemotherapy reported lower over-
all health-related quality of life scores compared with 
patients who did not receive chemotherapy.
Based on the results of the study, ESHAP not cost-effec-
tive as compared to IEV and it is  dominated because the 
expected cost was 20952.93 dollars and the expected 
QALY was 3.89 in the IEV arm whereas the expected cost 
was 31691.74 dollars and the expected QALY was 3.86 in 
the ESHAP arm. It can be stated that patients who had 
used the ESHAP had higher medical direct costs be-
cause of expensive chemotherapy and the higher mean 
of length of stay (5 days versus. 3 days) than IEV. Based 
on the results of the sensitivity analysis, the ICER was 
highly sensitive to QALY of patients who did not re-
spond to ESHAP and less sensitive to the cost of patients 
who did not respond to IEV. Overall, the results showed 
that IEV versus ESHAP was dominant in the treatment of 
patients with lymphoma. Also, ICER was -379463.42 dol-
lars (using IEV saves 379,463.42 dollars per each addi-
tional QALY). Therefore, it is recommended that oncolo-
gists should use IEV instead of ESHAP in the treatment 
of these patients. In addition, the results of the one-way 
and probabilistic sensitivity analysis powerfully sup-
port the conclusion that IEV regimen is a cost-effective 
option to ESHAP regimen. 
As to the generalizability of these findings, we can gen-
eralize these results to other Iranian hospitals, because 
of using IEV and ESHAP in the treatment of lymphoma 
therein. However, we  cannot generalize these results to 
other countries certainly due to differences in the costs 
covered by insurance organizations, the patients’ ability 
to pay, the incidence and prevalence of disease, differ-
ence in clinical guidelines, relative prices , payment sys-
tem and ceiling ratio.
This study had several limitations: first, due to time lim-
its all patients were studied during a course of treatment. 
Probably, different results would have been obtained if it 
had been done in a longer time period. Second, due to 
lack of studies in this field, using Markov models was not 
possible. Third, drug prices varied during the study so 
in relation with this case, the average prices were used. 
Fourth, due to the sensitivity of cancer patients about 
their disease, using the gentle way to communicate with 
them is essential. In addition, in this study we used the 
weighted scores of European quality of life questionnaire 
for measuring the utility of two regimens (IEV and ES-
HAP); therefore, the limitation of this questionnaire for 
Iranian setting must be considered and in future studies, 
it is suggested that researchers estimate these weighted 
scores for Iran.
Given the result of this study, it is suggested that IEV 
drugs be covered by insurance because of high costs of 
cancer patients or IEV drug costs be paid in health sec-
tors. When developing clinical guidelines for the treat-
ment of lymphoma, the government and the Ministry of 
Health should consider using IEV method by oncologists 
to reduce costs.
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